Infliximab does not lead to reduction in the interferon-gamma and lymphoproliferative responses of patients with moderate to severe psoriasis

Acta Dermato-Venereologica

Volumn 94, Issue 1, 2014, Pages 26-31

  Ortigosa, Luciena C M ^a   Silva, Léia C R ^b   Duarte, Alberto J S ^b   Takahashi, Maria D F ^b   Benard, Gil ^b  

^a UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cellular immune response; Infliximab; Interferon ; Psoriasis; TNF

Indexed keywords

GAMMA INTERFERON; INFLIXIMAB; MYCOBACTERIUM ANTIGEN; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR; VIRUS ONCOLYSATE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPHOCYTE; MALE; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; TREATMENT RESPONSE; TUBERCULIN TEST;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; CELLS, CULTURED; CYTOMEGALOVIRUS; ENTEROTOXINS; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHYTOHEMAGGLUTININS; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84890234528     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1650     Document Type: Article

References (38)

1. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol 2005; 153: 486-497.
2. Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, et al. Interferon-γ release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011; 23: 377-384.
3. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328.
4. Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the Quantifier On gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Infamm Bowel Dis 2011; 17: 2340-2349.
5. Kimura M, Converse PJ, Astemborski J, Rothel JS, Vlahov D, Comstock GW, et al. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis 1999; 179: 1297-1300.
6. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009; 36: 2158-2163.
7. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-806.
8. Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y, et al. Quantifier on TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Infamm Bowel Dis 2011; 17: 77-83.
9. Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H. Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012; 14: R147.
10. Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008; 67: 84-90.
11. Del Tedesco E, roblin X, Laharie D, Peyrin, Biroulet L. Does anti-TNF therapy influence the performance of myco-bacterium tuberculosis antigen-specific interferon-gamma assays? a French multicenter experience. Infamm Bowel Dis 2011; 17: 1824.
12. Silva LC, Silveira GG, Arnone M, Romiti R, Geluk A, Franken KC, et al. Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area. Arch Dermatol Res 2010; 302: 255-262.
13. DeAndrade Lima E, De Andrade Lima M, De Lorena VM, De Miranda Gomes Y, lupi O, et al. Evaluation of an IFN-gamma assay in the diagnosis of latent tuberculosis in patients with psoriasis in a highly endemic setting. Acta Derm Venereol 2011; 91: 694-697.
14. Abdel-Hamid MF, Aly DG, Saad NE, Emam HM, Ayoub DF. Serum levels of interleukin-8, tumor necrosis factor-α and γ-interferon in egyptian psoriatic patients and correlation with disease severity. J Dermatol 2011; 38: 442-446.
15. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010; 35: 645-649.
16. Roussaki-Schulze AV, kouskoukis C, Petinaki E, klimi E, Zafriou E, Galanos A, et al. Evaluation of cytokine serum levels in patients with plaque-type psoriasis. Int J Clin Pharmacol Res 2005; 25: 169-173.
17. Ettehadi P, Greaves MW, Wallach D Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-a) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
18. kapp A, Gillitzer R, kirchner H, Schöpf E. Decreased production of interferon in whole blood cultures derived from patients with psoriasis. J Invest Dermatol 1988; 90: 511-514.
19. Berg L, Lampa J, Rogberg S, van Vollenhoven R, kla-reskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF alpha receptors. Ann Rheum Dis 2001; 60: 133-139.
20. Baeten D, Van Damme N, Van den Bosch F, kruithof E, De Vos M, Mielants H. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF alpha. Ann Rheum Dis 2001; 60: 750-755.
21. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Bren-nan FM, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994; 94: 749-760.
22. Cope AP, liblau RS, Yang XD, Congia M, laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997; 185: 1573-1584.
23. Wakefeld PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. Am Acad Dermatol 1991; 24: 675-685.
24. Van Den Oord JJ, De Wolf Peeters. Epithelium-lining macrophages in psoriasis. C. Br J Dermatol 1994; 130: 589-594.
25. Wang H, Peters T, Kess D, Oreshkova T, Van rooijen N, et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin infammation. J Clin Invest 2006; 116: 2105-2114.
26. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 1997; 14: 145-153.
27. Fuentes-Duculan J, Suárez-Fariñas M, Zaba LC, Nograles KE, Pierson KC, Mitsui H, et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 2010; 130: 2412-2422.
28. Pigatto PD, Pigatto LB, Bigardi A, Altomare G, Finzi AF, et al. Factors secreted by untreated psoriatic monocytes enhance neutrophil functions. J Invest Dermatol 1990; 94: 372-376.
29. Djemadji-Oudjiel N, goerdt S, Kodelja V, Schmuth M, Orfanos CE. Immunohistochemical identifcation of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis. Arch Dermatol Res 1996; 288: 757-764.
30. Valledor AF, Comalada M, Santamaría-Babi LF, Lloberas J, Celada A. Macrophage proinflammatory activation and deactivation: a question of balance. Adv Immunol 2010; 108: 1-20.
31. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNF-alpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal kerati-nocyte differentiation. J Dermatol Sci 2007; 48: 87-101.
32. Silva LC, Geluk A, Arnone M, Romiti R, Franken Kc, Duarte AJ, et al. Infliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test. J Eur Acad Dermatol Venereol 2012; 26: 319-324.
33. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
34. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde VD, Pascual-Gómez E, Mola E, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
35. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132.
36. Jacobs M, Samarina A, Grivennikov S, Botha T, Allie N, Fremond C, et al. Review: Reactivation of tuberculosis by tumor necrosis factor neutralization. Eur Cytokine Netw 2007; 18: 5-13.
37. Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, Chan J, et al. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med 2000; 192: 347-358.
38. Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007; 12: 16-21.